OBJECTIVES: Care for cardiovascular diseases is an important issue for health care systems. Coronary artery bypass grafting surgery (CABG) is utilized to treat coronary artery disease.  Intensive care stay (ICS) and acute stroke (AS) are important drivers of post-operative costs.  In Turkey, ICS and AS receive add-on payments to the packaged payment for CABG from the Social Security Agency (SGK). Effective use of regional cerebral oxygen saturation monitoring (rSO2) during CABG reduces intensive care stay (ICS) from 1,87 to 1,25 days and acute stroke (AS) incidence from 2,21% to 0,61%. We modelled the potential impact of SGK add-on payment for rSO2 on SGK add-on payments for ICS and AS after CABG. METHODS: Turkish volume of CABG was estimated as 47.973 procedures for 2012 (Covidien ICD-10 study of Turkey), increasing at 7,2% per year (National Cardiology Policy Report). SGK was assumed to cover 75% of procedures.  ICS cost was taken from SGK. AS cost was taken from published data. Add-on payment for rSO2 was taken as 400TL per patient (cost of Covidien INVOS™ disposable sensor). Utilization of rSO2 in CABG with add-on payment was estimated as 15% in 2013, 30% in 2014, and 50% in 2015. Discount rate was 5%.  RESULTS: Under current care paradigms, estimated SGK cost for ICS and AS following CABG will be 82,9, 84,5 and 86,0 million TL in 2013, 2014 and 2015, respectively. However,  if add-on payment facilitates utilization and benefits of rSO2  in CABG, potential SGK cost for ICS and AS following CABG would decrease to 78,5, 75,3 and 70,6 million TL in those years. CONCLUSIONS: The cost of ICS and AS after CABG is substantial in Turkey.  Add-on payment for rSO2 during CABG may decrease cumulative ICS and AS costs by approximately 29 million TL between 2013 and 2015.